Sessile Serrated Polyps are Precursors of Colon Carcinomas With Deficient DNA Mismatch Repair

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 7, 2016, Pages 1056-1059

  Sweetser, Seth ^a   Jones, Andrea ^a   Smyrk, Thomas C ^a   Sinicrope, Frank A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Colon cancer; Genetics; MMR; Progression

Indexed keywords

B RAF KINASE; PROTEIN MLH1; BRAF PROTEIN, HUMAN; DNA LIGASE; MLH1 PROTEIN, HUMAN; MUTL PROTEIN HOMOLOG 1;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER STAGING; CLINICAL ARTICLE; COLON CARCINOMA; DISEASE ASSOCIATION; DYSPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MISMATCH REPAIR; MUTANT; PROTEIN EXPRESSION; RECTUM ADENOMA; SPLENIC FLEXURE; TUMOR LOCALIZATION; CARCINOMA; COHORT ANALYSIS; COLON TUMOR; COMPLICATION; CYTOCHEMISTRY; DEFICIENCY; MICROSCOPY; MIDDLE AGED; PATHOLOGY; POLYP; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MIDDLE AGED; MUTL PROTEIN HOMOLOG 1; POLYPS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84973644348     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.01.021     Document Type: Article

References (21)

1. Leggett B., Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010, 138:2088-2100.
2. Snover D.C. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011, 42:1-10.
3. Sweetser S., Smyrk T.C., Sinicrope F.A. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol 2013, 11:760-767. quiz e54-e55.
4. Spring K.J., Zhao Z.Z., Karamatic R., et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006, 131:1400-1407.
5. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50:113-130.
6. Sawhney M.S., Farrar W.D., Gudiseva S., et al. Microsatellite instability in interval colon cancers. Gastroenterology 2006, 131:1700-1705.
7. Sanduleanu S., le Clercq C.M., Dekker E., et al. Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature. Gut 2015, 64:1257-1267.
8. Capper D., Preusser M., Habel A., et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011, 122:11-19.
9. Sinicrope F.A., Mahoney M.R., Smyrk T.C., et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013, 31:3664-3672.
10. Kuan S.F., Navina S., Cressman K.L., et al. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. Hum Pathol 2014, 45:464-472.
11. Sinicrope F.A., Smyrk T.C., Tougeron D., et al. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer 2013, 119:2765-2770.
12. Day F., Muranyi A., Singh S., et al. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol 2015, 10:99-109.
13. Nolan S., Arnason T., Drucker A., et al. The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability. Appl Immunohistochem Mol Morphol 2014, 22:e8-e13.
14. Estrella J.S., Tetzlaff M.T., Bassett R.L., et al. Assessment of BRAF V600E status in colorectal carcinoma: tissue-specific discordances between immunohistochemistry and sequencing. Mol Cancer Ther 2015, 14:2887-2895.
15. Boparai K.S., Dekker E., Polak M.M., et al. A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome. Am J Pathol 2011, 178:2700-2707.
16. Bettington M., Walker N., Rosty C., et al. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. Gut 2015, Epub ahead of print.
17. Sheridan T.B., Fenton H., Lewin M.R., et al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions "caught in the act". Am J Clin Pathol 2006, 126:564-571.
18. Yang J.F., Tang S.J., Lash R.H., et al. Anatomic distribution of sessile serrated adenoma/polyp with and without cytologic dysplasia. Arch Pathol Lab Med 2015, 139:388-393.
19. Oono Y., Fu K., Nakamura H., et al. Progression of a sessile serrated adenoma to an early invasive cancer within 8 months. Dig Dis Sci 2009, 54:906-909.
20. Holme O., Bretthauer M., Eide T.J., et al. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut 2015, 64:929-936.
21. Nishihara R., Wu K., Lochhead P., et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013, 369:1095-1105.